Investigation of PSF and p53 binding sites in prostate ccancer cells
Proline- and glutamine-rich (PSF) has been identified as an important driver of aggressive cancers, in which PSF-RNA interactions promotes the expression of numerous oncogenic transcripts by modulating epigenetic and splicing systems. To develop small compounds targeting PSF as next generation therapeutic agents for hormone therapy refractory cancers, we performed small molecule library screen and identified the compound designated as No.10-3 as a potent PSF inhibitor. We further describe another small molecule C-30, an improved analog of No.10-3. PSF inhibits p53 epression in prostate cancer cells by epigenetic regulation.  We then  performed ChIP-seq analysis to determined PSF and p53 binding regions. Overall design: Identification of binding sites of PSF, and p53 in prostate cancer cell line, 22Rv1. In addition, PSF binding sites in DU145 prostate cancer cells bearing mutated p53 protein.